BUZZ-Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> shares more than double on promising cancer trial data** Intensity Therapeutics's shares INTS.O rocket 128.6% to $0.62 premarket
** Co's experimental cancer drug, INT230-6, showed encouraging results in patients with advanced cancers, according to a study published in Lancet's eBioMedicine
** INTS says INT230-6 showed 75% disease control rate in advanced cancers - eBioMedicine
** Drug injected directly into tumors; shrank untreated tumors in 20% of patients, co says
** Co Median survival was 11.9 months; rose to 21.3 months in sarcoma patients
** Up to last close, stock was down ~85% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.